Day: October 3, 2025

Maranello (Italy), October 3, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) will host its Capital Markets Day in Maranello (Italy) on October 9, 2025. A live webcast, commencing at 9:00 a.m. BST / 10:00 a.m. CEST / 4:00 a.m. EDT on Thursday, October 9, will be available on the Investors section of the Ferrari corporate website (https://www.ferrari.com/en-EN/corporate/capital-markets-day-2025). The webcast details, the presentations delivered during the event, and a replay video will remain archived on the same section of the corporate website for those unable to participate in the live session. For further information: Media Relations tel.: +39 0536 949337 Email: media@ferrari.com Investor Relations tel.: +39 0536 949695 Email: ir@ferrari.com    www.ferrari.comAttachmentPR_Instructions_CMD_ENG ...

Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only approved therapy for DMD in CanadaPratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in Canada. The Canadian Neuromuscular Disease registry estimates that there are more than 800 boys and young men living with DMD in Canada and coping with its debilitating symptoms. Kye Pharmaceuticals holds exclusive Canadian commercial rights to AGAMREE for the treatment of DMD and potentially other indications, following the agreement...

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1 First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC2 Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC*3Basel, 3 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with Tecentriq or Tecentriq...

Vancouver, B.C., Oct. 02, 2025 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) a digital asset and fintech platform bridging traditional capital markets with Web3 infrastructure, announces that it has been requested by OTC Markets Group Inc. (“OTC Markets”) to issue this statement about promotional activity concerning its common shares (the “Shares”) traded on the OTCQB Venture Market (“OTCQB”) (operated by OTC Markets). On September 29, 2025, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its Shares traded on the OTCQB, including the distribution of two newsletters (collectively, the “Promotional Materials”) published by Gold Standard Media LLC (“GSM”),...

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code assigned to Ryoncil® (remestemcel-L-rknd) by United States Medicare & Medicaid Services (CMS) became active for billing and reimbursement on October 1, 2025.1 Formal recognition by CMS is a significant milestone for Ryoncil® as the product becomes easier to bill and pay for. The new permanent J-Code, J3402, provides a standardized, clear, permanent, and specific billing pathway for Ryoncil® by Medicaid, facilitating reimbursement and broader patient access for this important therapy. Additionally, commercial payers look to the permanent J-code to update their coverage systems. Ryoncil®...